Imagine if a doctor could look at a standard scan for cancer and simultaneously spot early warning signs of heart disease or bone loss. This project builds a smart tool that scans routine images to find hidden risks for other serious illnesses. It's like having a second pair of expert eyes that checks for multiple health problems at once, helping patients get treatment sooner.
Breast cancer survivors often develop other chronic conditions like heart disease or osteoporosis that go undetected until they are severe. Current routine imaging is underutilized for this secondary prevention.
Trustworthy AI systems for risk prediction of cardiovascular disease, COPD, and osteoporosis, along with clinical manuals for tumour boards.
If you are a radiology AI developer dealing with the need for multi-disease screening — this project developed trustworthy AI systems that use CT scans to predict cardiovascular disease and osteoporosis. This allows your software to provide quantitative risk parameters for breast cancer patients.
If you are a radiotherapy clinic dealing with high patient volumes and complex comorbidities — this project developed AI tools ready for implementation at radiotherapy workstations. This enables your staff to start prompt treatment for chronic conditions based on objective data.
If you are an insurer dealing with the high cost of late-stage chronic disease in cancer survivors — this project developed risk prediction for lung disease and body composition. This helps in implementing risk-reducing strategies to improve long-term life expectancy.
Based on available project data, no specific pricing or cost information is provided.
Yes, the system is developed using a Real-World Data infrastructure containing CT scans and clinical data from over 26,000 patients, suggesting high scalability potential.
Based on available project data, specific IP and licensing terms are not mentioned.
The AI systems are designed for implementation at radiotherapy workstations and include manuals for multidisciplinary tumour boards to guide routine use.
The project period runs from 2023-05-01 to 2028-04-30, indicating the development and validation phase is ongoing.
The consortium is a diverse group of 11 partners across 5 countries, showing a strong mix of academic and commercial interests. With an 18% industry ratio (including 2 SMEs), the project balances deep research from 4 universities and 2 research institutes with practical market application. The inclusion of the largest breast cancer patient advocacy organisation in Europe ensures the end-user needs are integrated into the development process.
Contact Universitaire Medisch Centrum Utrecht in the Netherlands
Contact us to explore licensing opportunities for these AI risk-prediction tools.
